Who founded Neurona Therapeutics?

Neurona Therapeutics was founded by Cory Nicholas.

Who are Neurona Therapeutics's investors?

Neurona Therapeutics's investors include Berkeley Frontier, Iaso Ventures, The Column Group, Ysios Capital, Alexandria, Fidelity Investments, LYFE Capital, Soleus Capital and 6 more.

How much funding has Neurona Therapeutics raised?

Neurona Therapeutics has disclosed $347.5M raised across 6 rounds.

Where is Neurona Therapeutics headquartered?

Neurona Therapeutics is headquartered in South San Francisco, US.

Neurona Therapeutics

South San Francisco, US · 21 known investors

Find your way into Neurona Therapeutics

615 people in our graph share verified history with the Neurona Therapeutics team — schools, employers, funds. One of them is your warm intro.

Kelli McKeirnanunlockedknows Eduardo Dunayevich · together at Amgen (overlapped)

×3knows the team · via Rockefeller University

×2knows the team · via University of Buenos Aires

×2knows the team · via Bayer Biotechnology

×4knows the team · via Amgen

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system. Founded by neuroscientists and stem cell researchers from UC San Francisco, it operates a regenerative medicine discovery platform and manufactures neuronal, glial, and gene-edited cell therapy candidates in its own cGMP facility.

Biotech Deep Tech Healthtech

Founders & leadership

Cory NicholasinFounder · CEO

James StutzinChief Financial Officer / Chief Business Officer

Catherine Priest inChief Development OfficerChief Development Officer of Neurona Therapeutics. Priest has experience in neuroscience and cellular therapeutics development, with background spanning industry, government, and academia, and has led work advancing cellular therapies through IND approval and clinical trials.

Gautam Banik inChief Technology OfficerGautam Banik is Chief Technology Officer of Neurona Therapeutics, where he leads manufacturing and process development for cell therapies. He brings experience in cell line development, bioprocess scale-up, cGMP manufacturing, regulatory filings, and technology transfer across recombinant protein, cell therapy, and gene therapy platforms.

Eduardo Dunayevich inChief Medical OfficerEduardo Dunayevich is a psychiatrist with over two decades of pharmaceutical industry experience spanning psychiatry, neurology, metabolic, and autoimmune disorders across small and large molecule programs from pre-IND through Phase IV, including regulatory submissions and approvals. He has held clinical and executive leadership roles and served on governance, data monitoring, and steering committees.

Arnold KriegsteinNamed on SEC filing

Board

Peter Svennilson inBoard directorFounder / Managing Partner at The Column Group

Tim KutzkeyBoard director

Ray KelleherBoard director

Leo GuthartBoard director

David Goeddel inBoard directorManaging Partner at The Column Group

Brad MargusBoard director

Investors · 21

Berkeley FrontierBerkeley

Iaso VenturesCambridge

The Column GroupSan Francisco · $30M

Ysios CapitalBarcelona · $5.4M – $21.6M

AlexandriareportedPasadena

Fidelity InvestmentsreportedBoston

LYFE CapitalreportedMenlo Park

Soleus CapitalreportedGreenwich

Spur Capital PartnersreportedBoston

SymBiosisreportedBentonville

UCB VenturesreportedBrussels

Viking Global InvestorsreportedStamford

Willett AdvisorsreportedNew York

YK BioventuresreportedBurlingame

Also in the syndicate · 7

Cormorant Asset ManagementEuclidean CapitalPassaic Capital ManagementSchroders CapitalSphera Biotech Master Fund LPUC InvestmentsYsios Capital Partners

Reported raises · per SEC filings

Form D private placements

$347.5M disclosed across 6 rounds · 2014–2025

▶$101.7MraisedApr 2025 · 46 investors · Biotechnology

Rule 506(b)